Holen Sie sich die Stockscreener-App
1.45
1.40%
0.02
Handel nachbörslich:
1.43
-0.02
-1.38%
Schlusskurs vom Vortag:
$1.43
Offen:
$1.44
24-Stunden-Volumen:
369.38K
Relative Volume:
0.68
Marktkapitalisierung:
$75.85M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-0.8101
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
+9.85%
1M Leistung:
-9.38%
6M Leistung:
-69.60%
1J Leistung:
-83.41%
1-Tages-Spanne:
$1.41
$1.475
1-Wochen-Bereich:
$1.33
$1.50
52-Wochen-Spanne:
$1.02
$9.29
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.45 | 68.47M | 21.05M | -89.22M | -64.50M | -1.79 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewswire
Cancer Therapy Pioneer TScan Therapeutics Set for Major Presentation at Jefferies Healthcare Conference - Stock Titan
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Canada
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
New Data and Deal Flow Signal a Turning Point for Precision-Driv - GuruFocus
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Comparing TScan Therapeutics (NASDAQ:TCRX) and Twist Bioscience (NASDAQ:TWST) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Dimensional Fund Advisors LP Increases Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Stifel Financial Corp Acquires 10,567 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Barclays PLC - Defense World
H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating - Investing.com Nigeria
Equities Analysts Set Expectations for TCRX Q2 Earnings - Defense World
Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World
Wedbush Research Analysts Reduce Earnings Estimates for TCRX - Defense World
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $10.00 - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Position Trimmed by Renaissance Technologies LLC - Defense World
Brokers Offer Predictions for TCRX Q1 Earnings - Defense World
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
TScan Therapeutics (TCRX) Price Target Lowered by HC Wainwright | TCRX Stock News - GuruFocus
What Analysts Are Saying About TScan Therapeutics Stock - Benzinga
TScan Therapeutics Reports Q1 2025 Financial Results - TipRanks
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics (TCRX) Exceeds Q1 Revenue Expectations | TCRX Stock News - GuruFocus
TScan Therapeutics Reveals Solid Progress: Key Clinical Data Coming in 2025, $251M War Chest Secured - Stock Titan
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average Target Price from Brokerages - Defense World
JPMorgan Chase & Co. Acquires 34,951 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BlackRock, Inc. Reduces Stake in TScan Therapeutics Inc by 43.05% - GuruFocus
Geode Capital Management LLC Has $2.93 Million Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting - Nasdaq
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting - Yahoo
What is the investor’s view on Tscan Therapeutics Inc (TCRX)? - uspostnews.com
Investing in Tscan Therapeutics Inc (TCRX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
Prudential Financial Inc. Acquires Shares of 10,415 TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average PT from Brokerages - Defense World
TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga
Monitoring Gentherm Inc (THRM) after recent insider movements - knoxdaily.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - Defense World
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Tscan Therapeutics Inc [TCRX] Shares Fall Approximately -81.72% Over the Year - Knox Daily
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - Quantisnow
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
TScan Therapeutics’ (TCRX) Overweight Rating Reiterated at Morgan Stanley - The AM Reporter
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
8.70%
1.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):